Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

41. Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May

2019 CADTH - Pan Canadian Oncology Drug Review

42. Pembrolizumab (Keytruda) - metastatic non-squamous non-small cell lung carcinoma (NSCLC)

is summarised as follows: ADVICE: following a resubmission assessed under the end of life process pembrolizumab (Keytruda ® ) is accepted for restricted use within NHSScotland. Indication under review: in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations. SMC restriction: in patients whose tumours express programmed death ligand 1 (PD-L1 (...) accepted pembrolizumab for restricted use in NHSScotland. Other data were also assessed but remain confidential.* Additional information: guidelines and protocols The Scottish Intercollegiate Guidelines Network (SIGN) published guideline number 137, Management of lung cancer in February 2014. The guidance recommends that patients who have advanced disease, are performance status 0 to 1, have predominantly non-squamous NSCLC and are EGFR mutation negative should be offered combination systemic

2019 Scottish Medicines Consortium

43. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review

44. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

45. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

46. ALK Inhibitors for Non–Small Cell Lung Cancer

of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and are the treatment of choice in the first-line and subsequent line settings. This drug class is expanding and new products are poised to enter the market. Reviews of the comparative clinical and cost-effectiveness of ALK inhibitors, and of guidelines pertaining to their use, were requested by Canadian decision-makers (...) ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer | CADTH.ca Find the information you need ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer Last updated: February 20, 2019 Project Number: HE0017-000 Product Line: Technology Review Result type: Report Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement

2019 CADTH - Technology Review

47. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (Abstract)

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.In this open-label, phase 3 trial, we randomly assigned

2019 NEJM

48. Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment

Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment Daily online image-guided radiotherapy (lung cancer) - Health Technology Wales > Daily online image-guided radiotherapy (lung cancer) Daily online image-guided radiotherapy (lung cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health (...) Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER036 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full

2019 Health Technology Wales

49. Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma

Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma Stereotactic ablative body radiotherapy - Health Technology Wales > Stereotactic ablative body radiotherapy Stereotactic ablative body radiotherapy Topic Status Complete Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer (...) Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER041 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm

2019 Health Technology Wales

50. Volumetric modulated arc radiotherapy for people with lung cancer

Volumetric modulated arc radiotherapy for people with lung cancer Volumetric modulated arc radiotherapy (lung cancer) - Health Technology Wales > Volumetric modulated arc radiotherapy (lung cancer) Volumetric modulated arc radiotherapy (lung cancer) Topic Status Complete Volumetric modulated arc radiotherapy for people with lung cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre (...) . It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER034 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking

2019 Health Technology Wales

51. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)- activating mutations. 1 Dosing Information EGFR mutation status should be established prior to initiation of dacomitinib therapy. The recommended dose of dacomitinib is 45mg taken orally once daily, until disease progression or unacceptable toxicity occurs. Patients should be encouraged to take their dose at approximately the same time each day. Dose modifications may be required based on individual safety and tolerability (...) as adenocarcinoma. Those with recurrent disease were required to have a disease-free interval of =12-months between completing adjuvant or neoadjuvant therapy and recurrence. Patients also had at least one confirmed EGFR mutation (Ex19del or L858R mutation with or without T790M mutation) and at least one measurable target lesion (according to Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) that had not previously been irradiated. They also had Eastern Co-operative Oncology Group (ECOG

2019 Scottish Medicines Consortium

52. Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC)

. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. 1 Dosing Information Osimertinib 80mg orally once daily (at the same time each day) until disease progression or unacceptable (...) patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations. Clinical expert responses indicate afatinib and erlotinib are the key comparators and afatinib may be the treatment most likely to be displaced in practice, particularly for fitter patients. A partitioned survival model was used with three health states: progression free, progressed disease and death. The model used PFS and OS data to model events over a 20-year time horizon. The source of the clinical data

2019 Scottish Medicines Consortium

53. Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults.

as follows: ADVICE: following a full submission assessed under the end of life medicine process pembrolizumab (Keytruda ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with carboplatin and either paclitaxel or nab- paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults. SMC restriction: in combination with carboplatin and paclitaxel in patients whose tumours express programmed death ligand 1 (PD-L1 (...) CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001;92(10):2639-47. 9. Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, et al. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer in China. Clinical Therapeutics. 2019. 10. Dynamed Plus. Management of advanced

2019 Scottish Medicines Consortium

54. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

this. It does not meet the end-of-life criteria when compared with pembrolizumab monotherapy for people whose tumours express PD-L1 with a tumour proportion score of 50% or higher. Pembrolizumab should be stopped at 2 years of uninterrupted treatment or earlier if disease progresses because the clinical- and cost-effectiveness evidence is limited to Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600) © NICE 2019. All rights reserved. Subject (...) 1.1 Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non- small-cell lung cancer (NSCLC) in adults only if: pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and the company provides pembrolizumab according to the managed access agreement. 1.2 This recommendation is not intended to affect treatment with pembrolizumab, with carboplatin and paclitaxel

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

55. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. (Abstract)

lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer. (...) Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients

2019 JAMA

56. Lorbrena - anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorbrena - anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

57. Durvalumab (Imfinzi) for the treatment of locally advanced, unresectable, non-small cell lung cancer

Durvalumab (Imfinzi) for the treatment of locally advanced, unresectable, non-small cell lung cancer Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer | Report | National Health Care Institute You are here: Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer Search within English part of National Health Care Institute Search Durvalumab (Imfinzi®) for the treatment of locally advanced (...) , unresectable, non-small cell lung cancer Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally advanced, unresectable, non-small cell lung cancer (NSCLC). Due to its expected high costs the Minister of Health, Welfare and Sport (VWS) has placed durvalumab in the so-called ‘waiting room’ or ‘sluice’ for expensive drugs. These products can only be accepted into the insured package after the Zorginstituut has advised on their inclusion

2019 National Health Care Institute (Zorginstituut Nederland)

58. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

there is no difference between dacomitinib and afatinib in terms of how long people live or how long it is before their disease gets worse. There is some uncertainty about the assumptions used in the cost-effectiveness modelling. But the most plausible cost-effectiveness estimate is within what NICE normally considers an acceptable use of NHS resources. So dacomitinib is recommended. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595) © NICE 2019. All rights reserved. Subject (...) papers for full details of the evidence. Clinical need P People would welcome a new treatment option eople would welcome a new treatment option 3.1 The patient experts highlighted that epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) tends to present late, so people have more advanced disease at diagnosis compared with the wider NSCLC population. The patient experts also noted that dacomitinib may improve overall survival, which is especially important

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

59. Interventions for smoking cessation in people diagnosed with lung cancer. (Abstract)

Interventions for smoking cessation in people diagnosed with lung cancer. Lung cancer is one of the most common causes of death from cancer worldwide. Smoking induces and aggravates many health problems, including vascular diseases, respiratory illnesses and cancers. Tobacco smoking constitutes the most important risk factor for lung cancer. Most people with lung cancer are still active smokers at diagnosis or frequently relapse after smoking cessation. Quitting smoking is the most effective (...) way for smokers to reduce the risk of premature death and disability. People with lung cancer may benefit from stopping smoking. Whether smoking cessation interventions are effective for people with lung cancer and whether one method of quitting is more effective than any other has not been systematically reviewed.To determine the effectiveness of smoking cessation programmes for people with lung cancer.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (accessed via

2019 Cochrane

60. Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis (Abstract)

circulating tumor cells (FR+CTCs) after surgery and 5-year overall, disease-free, and lung cancer-specific survival.A total of 86 individuals were randomized; 22 patients (25.6%) were younger and 64 (74.4%) older than 60 years. Of these, 78 patients were analyzed. After surgery, an incremental change in FR+CTCs was observed in 26 of 40 patients (65.0%) in the artery-first group and 12 of 38 (31.6%) in the vein-first group (P = .003) (median change, 0.73 [interquartile range (IQR), -0.86 to 1.58] FU per 3 (...) Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis It is important to develop a surgical technique to reduce dissemination of tumor cells into the blood during surgery.To compare the outcomes of different sequences of vessel ligation during surgery on the dissemination of tumor cells and survival in patients with non-small

2019 EvidenceUpdates